Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioRestorative Therapies Inc BRTX

BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured... see more

Recent & Breaking News (NDAQ:BRTX)

BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome

TheNewsWire March 9, 2023

BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023

GlobeNewswire March 7, 2023

BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

GlobeNewswire March 2, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

TheNewsWire February 10, 2023

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

GlobeNewswire February 8, 2023

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

TheNewsWire February 3, 2023

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

TheNewsWire January 26, 2023

BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event

Newsfile January 17, 2023

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

GlobeNewswire December 6, 2022

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

GlobeNewswire December 5, 2022

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

GlobeNewswire November 29, 2022

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

GlobeNewswire November 16, 2022

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

TheNewsWire November 10, 2022

See What’s Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!

TheNewsWire October 31, 2022

BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

GlobeNewswire October 20, 2022

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

TheNewsWire October 14, 2022

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

GlobeNewswire September 28, 2022

BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

GlobeNewswire September 27, 2022

BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14

GlobeNewswire September 7, 2022

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

TheNewsWire September 1, 2022